KIT- INCLUDES 10MG VIAL , RECONSTITUTION WATER AND 6 SYRINGES
RETATRUTIDE (also known by its research code LY3437943) is an investigational peptide medication that acts as a triple-receptor agonist to treat obesity and type 2 diabetes. It is not yet approved by the FDA for any use, though it is in late-stage clinical trials.
HOW IT WORKS
Retatrutide is a "triple G" agonist, meaning it mimics the actions of three natural hormones in the body simultaneously:
GLP-1 (Glucagon-like peptide-1): Helps lower blood sugar, slow gastric emptying, and reduce appetite.
GIP (Glucose-dependent insulinotropic polypeptide): Also helps regulate blood sugar by promoting insulin release and contributes to appetite reduction.
Glucagon: Promotes the breakdown of stored fat for energy use, increasing energy expenditure.
This triple action distinguishes it from other weight loss drugs like semaglutide (Ozempic/Wegovy), which only targets GLP-1 receptors, and tirzepatide (Mounjaro/Zepbound), which targets GLP-1 and GIP receptors.
EFFICACY AND STATUS
Clinical trials have shown promising results, with participants experiencing an average weight loss of up to 24.2% over 48 weeks at the highest dose.
IMPORTANT CONSIDERATIONS:
Not FDA Approved: Retatrutide is still in Phase 3 clinical trials, led by Eli Lilly. Final approval is not expected until at least mid-to-late 2026 or early 2027.
THIS IS A RESEARCH PRODUCT not intended for human consumption by the FDA
COMMON SIDE EFFECTS: The most common side effects reported in trials are gastrointestinal, including nausea, diarrhea, vomiting, and constipation.
PEPTIDES AREA NON-REFUNDABLE. PLEASE MAKE YOUR SELECTION CAREFULLY
While taking GLP-1 Type medications, supplements are primarily used to prevent nutrient deficiencies caused by reduced food intake and to manage common side effects like muscle loss and constipation.
